Sanofi Cenrifki EU Approval Marks a New Phase in Progressive MS Treatment
Sanofi Cenrifki has received European Commission approval for the treatment of secondary progressive multiple sclerosis without relapses in the last two years, giving the company a major regulatory milestone in neurology and offering a new option for a difficult-to-treat stage of multiple sclerosis. The approval positions Cenrifki, also known as
